Abstract

Oncological diseases, due to the still increasing morbidity and mortality, are one of the main problems of modern medicine. Cancer of the mammary gland is the most common cancer among women around the world, and is the second cause of cancer deaths in this group, immediately after lung cancer. This kind of cancer belongs to an estrogen-dependent cancer, with proven associations with hormonal disorders in the body, occurring especially in the perimenopausal period and among women using hormone replacement therapy, as well as a result of the action of various xenobiotics that may interact with the estrogen receptor. Hormone steroids are widely used in medicine and their side effects are constantly discussed. The role of these compounds and their metabolites in maintaining hormonal balance is well understood, while many studies indicate the possible contribution of these steroids in the progression of the cancer process, especially in mammary gland tissue. Therefore, the genotoxic action of this group of compounds is still studied. Due to the limited number of scientific reports, the aim of this paper was to review and critically analyze data from the literature regarding the participation of estrogens (17β-estradiol) and their metabolites (2-methoxy estradiol, 4-hydroxy estradiol, 16α-hydroxyestrone) in the induction of carcinogenesis in mammary gland, in particular concerning the genotoxic activity of 17β-estradiol metabolites.

References

• 1. Ayyanan A., Laribi O., Schuepbach-Mallepell S., Schrick C., GutierrezM., Tanos T., Lefebvre G., Rougemont J., Yalcin-Ozuysal Ö.,Brisken C.: Perinatal exposure to bisphenol A increases adult mammarygland progesterone response and cell number. Mol. Endocrinol.,2011; 25: 1915–1923
  Google Scholar
• 2. Bajpayee M., Pandey A.K., Parmar D., Mathur N., Seth P.K., DhawanA.: Comet assay responses in human lymphocytes are not influencedby the menstrual cycle: a study in healthy Indian females.Mutat. Res., 2005; 565: 163–172
  Google Scholar
• 3. Batsi C., Markopolou S., Kontargiris E., Charalambous C., ThomasC., Christoforidis S., Kanavaros P., Constantinou A.I., Marcu K.B.,Kolettas E.: Bcl-2 blocks 2-methoxyestradiol induced leukemia cellapoptosis by a p27 Kip1-dependent G1/S cell cycle arrest in conjunctionwith NF-κB activation. Biochem. Pharmacol., 2009; 78: 33–44
  Google Scholar
• 4. Byrne C., Divekar S.D., Storchan G.B., Parodi D.A., Martin M.B.: Metalsand breast cancer. J. Mammary Gland Biol. Neoplasia, 2013; 18: 63–73
  Google Scholar
• 5. Chen ZH.., Na H.K., Hurh Y.J., Surh Y.J.: 4-hydroksyestradiol inducesoxidative stress and apoptosis in human mammary epithelialcells: Possible protection by NF-κB and ERK/MAPK. Toxicol. Appl.Pharmacol., 2005; 208: 46–56
  Google Scholar
• 6. Chmielewska M., Skibińska I., Kotwicka M.: Mitochondria jakoorganelle docelowe dla działania estrogenów. Postępy Hig. Med.Dośw., 2017; 71: 454–465
  Google Scholar
• 7. Dhillon V.S., Dhillon I.K.: Genotoxicity evaluation of estradiol.Mutat. Res., 1995; 345: 87–95
  Google Scholar
• 8. Dingli D., Timm M., Russell S.J., Witzig T.E., Rajkumar S.V.: Promisingpreclinical activity of 2-methoxyestradiol in multiple myeloma.Clin. Cancer Res., 2002; 8: 3948–3954
  Google Scholar
• 9. Drevon C., Piccoli C., Montesano R.: Mutagenicity assays of estrogenichormones in mammalian cells. Mutat. Res., 1981; 89: 83–90
  Google Scholar
• 10. Foksiński M., Piekutowski K., Roszkowski K., Oliński R.: Rola estrogenóww procesie karcinogenezy. Współcz. Onkol., 2002; 3: 137–140
  Google Scholar
• 11. Fortner R.T., Oh H., Daugherty S.E., Xu X., Hankinson S.E., ZieglerR.G., Eliassen A.H.: Analgesic use and patterns of estrogen metabolismin premenopausal women. Horm. Cancer, 2014; 5: 104–112
  Google Scholar
• 12. Fuhrman B.J., Schairer C., Gail M.H., Boyd-Morin J., Xu X.,Sue L.Y., Buys S.S., Isaacs C., Keefer L.K., Veenstra T.D., Berg C.D.,Hoover R.N., Ziegler R.G.: Estrogen metabolism and risk of breastcancer in postmenopausal women. J. Natl. Cancer Inst., 2012;104: 326–339
  Google Scholar
• 13. Górska M., Kuban-Jankowska A., Zmijewski M., Marino GammazzaA., Cappello F., Wnuk M., Gorzynik M., Rzeszutek I., Daca A.,Lewinska A., Wozniak M.: DNA strand breaks induced by nuclearhijacking of neuronal NOS as an anti-cancer effect of 2- methoxyestradiol.Oncotarget, 2015; 6: 15449–15463
  Google Scholar
• 14. Górska M., Zmijewski M.A., Kuban-Jankowska A., Wnuk M., RzeszutekI., Wozniak M.: Neuronal nitric oxide synthase-mediated genotoxicityof 2-methoxyestradiol in hippocampal HT22 cell line.Mol. Neurobiol., 2016; 53: 5030–5040
  Google Scholar
• 15. Gray J.M., Rasanayagam S., Engel C., Rizzo J.: State of the evidence2017: an update on the connection between breast cancer andthe environment. Environ. Health, 2017; 16: 94
  Google Scholar
• 16. Han X., Liehr J.G.: DNA single-strand breaks in kidneys of Syrianhamsters treated with steroidal estrogens: hormone-inducedfree radical damage preceding renal malignancy. Carcinogenesis,1994; 15: 997–1000
  Google Scholar
• 17. Han X., Liehr J.G.: Microsome-mediated 8-hydroxylation of guaninebases of DNA by steroid estrogens: correlation of DNA damageby free radicals with metabolic activation to quinones. Carcinogenesis,1995; 16: 2571–2574
  Google Scholar
• 18. Hayashi N., Hasegawa K., Komine A., Tanaka Y., McLachian J.A.,Barrett J.C., Tsutsui T.: Estrogen-induced cell transformation andDNA adduct formation in cultured Syrian hamster embryo cells.Mol. Carcinog., 1996; 16: 149–156
  Google Scholar
• 19. Hernández L.G., van Benthem J., Johnson G.E.: A mode-of-actionapproach for the identification of genotoxic carcinogens. PLoSOne, 2013; 8: e64532
  Google Scholar
• 20. Hosford S.R., Shee K., Wells J.D., Traphagen N.A., Fields J.L.,Hampsch R.A., Kettenbach A.N., Demidenko E., Miller T.W.: Estrogentherapy induces an unfolded protein response to drive cell death inER+ breast cancer. Mol. Oncol., 2019; 13: 1778–1794
  Google Scholar
• 21. Iso T., Watanabe T., Iwamoto T., Shimamoto A., Furuichi Y.: DNAdamage caused by bisphenol A and estradiol through estrogenic activity.Biol. Pharm. Bull., 2006; 29: 206–210
  Google Scholar
• 22. Joosten H.F., van Acker F.A., van den Dobbelsteen D.J., HorbachG.J., Krajnc E.I.: Genotoxicity of hormonal steroids. Toxicol. Lett.,2004; 151: 113–134
  Google Scholar
• 23. Ke H., Suzuki A., Miyamoto T., Kashima H., Shiozawa T.: 4-hydroxyestrogeninduces DNA damage on codon 130/131 of PTEN inendometrial carcinoma cells. Mol. Cell. Endocrinol., 2015; 400: 71–77
  Google Scholar
• 24. Khoei S., Delfan S., Neshasteh-Riz A., Mahdavi S.R.: Evaluationof the combined effect of 2ME2 and 60Co on the inducementof DNA damage by IUdR in a spheroid model of the U87MGglioblastoma cancer cell line using alkaline comet assay. Cell J.,2011; 13: 83–90
  Google Scholar
• 25. Kong L.Y., Szaniszlo P., Albrecht T., Liehr J.G.: Frequency and molecularanalysis of hprt mutations induced by estradiol in Chinesehamster V79 cells. Int. J. Oncol., 2000; 17: 1141–1149
  Google Scholar
• 26. Lang R., Reimann R.: Studies for a genotoxic potential of someendogenous and exogenous sex steroids. I. Communication: examinationfor the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells. Environ. Mol.Mutagen., 1993; 21: 272–304
  Google Scholar
• 27. LaVallee T.M., Zhan X.H., Herbstritt C.J., Kough E.C., Green S.J.,Pribluda V.S.: 2-Methoxyestradiol inhibits proliferation and inducesapoptosis independently of estrogen receptors α and β. Cancer Res.,2002; 62: 3691–3697
  Google Scholar
• 28. Licznerska B., Baer-Dubowska W.: Intrakrynologia estrogenówa terapia i chemioprewencja w nowotworach piersi. Postępy Hig.Med. Dośw., 2010; 64: 220–230
  Google Scholar
• 29. Loeb L.A., Harris C.C.: Advances in chemical carcinogenesis:a historical review and prospective. Cancer Res., 2008; 68: 6863–6872
  Google Scholar
• 30. Lu Y., Liu Y., Yang C.: Evaluating in vitro DNA damage usingcomet assay. J. Vis. Exp., 2017; 2017: e56450
  Google Scholar
• 31. Makowski M., Połać I., Pertyński T.: Estrogeny a rak sutka. Prz.Menopauz., 2007; 3: 150–154
  Google Scholar
• 32. Matejczyk M., Zalewski P.: Związki endokrynnie aktywne i ichaktywność biologiczna. Kosmos, 2011; 1–2: 17–32
  Google Scholar
• 33. Mauras N., Santen R.J., Colón-Otero G., Hossain J., Wang Q.,Mesaros C., Blair I.A.: Estrogens and their genotoxic metabolitesare increased in obese prepubertal girls. J. Clin. Endocrinol. Metab.,2015; 100: 2322–2328
  Google Scholar
• 34. McGowan E.M., Lin Y., Hatoum D.: Good guy or bad guy? The dualityof wild-type p53 in hormone-dependent breast cancer origin,treatment, and recurrence. Cancers, 2018; 10: E172
  Google Scholar
• 35. Mueck A.O., Seeger H., Lippert T.H.: Estradiol metabolism andmalignant disease. Muturitas, 2002; 43: 1–10
  Google Scholar
• 36. Nohmi T.: Thresholds of genotoxic and non-genotoxic carcinogens.Toxicol. Res., 2018; 34: 281–290
  Google Scholar
• 37. Park S.A., Lee M.H., Na H.K., Surh Y.J.: 4-Hydroxyestradiol inducesmammary epithelial cell transformation through Nrf2-mediatedheme oxygenase-1 overexpression. Oncotarget, 2017; 8: 164–178
  Google Scholar
• 38. Pietrzak B., Wlaźlak E., Zwierzyńska E.: Estrogeny stosowanedługotrwale: korzyści czy ryzyko. Postępy Hig. Med. Dośw., 2015;69: 285–293
  Google Scholar
• 39. Pogribny I.P., Rusyn I., Beland F.A.: Epigenetic aspects of genotoxicand non-genotoxic hepatocarcinogenesis: studies in rodents.Environ. Mol. Mutagen., 2008; 49: 9–15
  Google Scholar
• 40. Pruthi S., Yang L., Sandhu N.P., Ingle J.N., Beseler C.L., SumanV.J., Cavalieri E.L., Rogan E.G.: Evaluation of serum estrogen-DNAadducts as potential biomarkers for breast cancer risk. J. SteroidBiochem. Mol. Biol., 2012; 132: 73–79
  Google Scholar
• 41. Rajapakse N., Butterworth M., Kortenkamp A.: Detection ofDNA strand breaks and oxidized DNA bases at the single-cell levelresulting from exposure to estradiol and hydroxylated metabolites.Environ. Mol. Mutagen., 2005; 45: 397–404
  Google Scholar
• 42. Richold M.: The genotoxicity of trenbolone, a synthetic steroid.Arch. Toxicol., 1988; 61: 249–258
  Google Scholar
• 43. Saczko J., Choromańska A., Rembiałkowska N., Dubińska-MagieraM., Bednarz-Misa I., Bar J., Marcinkowska A., Kulbacka J.: Oxidativemodification induced by photodynamic therapy with Photofrin1IIand 2-methoxyestradiol in human ovarian clear carcinoma (OvBH-1) and human breast adenocarcinoma (MCF-7) cells. Biomed. Pharmacother.,2015; 71: 30–36
  Google Scholar
• 44. Saczko J., Michel O., Chwiłkowska A., Sawicka E., Mączyńska J.,Kulbacka J.: Estrogen receptors in cell membranes: Regulation andsignaling. Adv. Anat. Embryol. Cell Biol., 2017; 227: 93–105
  Google Scholar
• 45. Santen R.J., Yue W., Wang J.P.: Estrogen metabolites and breastcancer. Steroids, 2015; 99: 61–66
  Google Scholar
• 46. Sawicka E., Długosz A.: The role of 17β-estradiol metabolitesin chromium-induced oxidative stress. Adv. Clin. Exp. Med., 2017;26: 215–221
  Google Scholar
• 47. Sawicka E., Piwowar A., Musiala T., Dlugosz A.: The estrogens/chromium interaction in the nitric oxide generation. Acta Pol.Pharm., 2017; 74: 785–791
  Google Scholar
• 48. Sepkovic D.W., Bradlow H.L.: Estrogen hydroxylation – the goodand the bad. Ann. N.Y. Acad. Sci., 2009; 1155: 57–67
  Google Scholar
• 49. Singh S.: Zinc oxide nanoparticles impacts: cytotoxicity, genotoxicity,developmental toxicity, and neurotoxicity. Toxicol. Mech.Methods, 2019; 29: 300–311
  Google Scholar
• 50. Song R.X., Mor G., Naftolin F., McPherson R.A., Song J., Zhang Z.,Yue W., Wang J., Santen R.J.: Effect of long-term estrogen deprivationon apoptotic responses of breast cancer cells to 17β-estradiol.J. Natl. Cancer Inst., 2001; 93: 1714–1723
  Google Scholar
• 51. Stetkiewicz T., Stachowiak G., Pakalski A., Makuła A., SurkontG., Pertyński T.: Kontrowersje wokół antyoksydacyjnego działaniaestrogenów. Prz. Menopauz., 2006; 6: 343–346
  Google Scholar
• 52. Świtalska M., Strządała L.: Niegenomowe działanie estrogenów.Postępy Hig. Med. Dośw., 2007; 61: 541–547
  Google Scholar
• 53. Tripathi K., Mani C., Somasagara R.R., Clark D.W., AnanthapurV., Vinaya K., Palle K.: Detection and evaluation of estrogen DNAadductsand their carcinogenic effects in cultured human cells usingbiotinylated estradiol. Mol. Carcinog., 2017; 56: 1010–1020
  Google Scholar
• 54. Tsutsui T., Suzuki N., Fukuda S., Sato M., Maizumi H., McLachlanJ.A., Barrett J.C.: 17β-estradiol-induced cell transformation andaneuploidy of Syrian hamster embryo cells in culture. Carcinogenesis,1987; 8: 1715–1719
  Google Scholar
• 55. Tsutsui T., Tamura Y., Hagiwara M., Miyachi T., Hikiba H., KuboC., Barrett J.C.: Induction of mammalian cell transformation andgenotoxicity by 2 methoxyestradiol, an endogenous metabolite ofestrogen. Carcinogenesis, 2000; 21: 735–740
  Google Scholar
• 56. Tsutsui T., Tamura Y., Yagi E., Barrett J.C.: Involvement ofgenotoxic effects initiation of estrogens-inducted cellular transformation:studies using Syrian hamster embryo cells treatedwith 17β-estradiol and eight of its metabolites. Int. J. Cancer,2000; 86: 8–14
  Google Scholar
• 57. Visagie M.H., Joubert A.M.: 2-Methoxyestradiol-bis-sulfamateinduces apoptosis and autophagy in a tumorigenic breast epithelialcell line. Mol. Cell. Biochem., 2011; 357: 343–352
  Google Scholar
• 58. Wen C., Wu L., Fu L., Wang B., Zhou H.: Unifying mechanism inthe initiation of breast cancer by metabolism of estrogen (Review).Mol. Med. Rep., 2017; 16: 1001–1006
  Google Scholar
• 59. Witczak K., Sajdak S., Kojs Z.: Hormonalna terapia zastępczaw ginekologii onkologicznej. Curr. Gynecol. Oncol., 2013; 11: 62–73
  Google Scholar
• 60. Yamazaki S., Sakakibara H., Takemura H., Yasuda M., ShimoiK.: Quercetin-3-O-glucronide inhibits noradrenaline binding to α2-adrenergic receptor, thus suppressing DNA damage induced by treatmentwith 4-hydroxyestradiol and noradrenaline in MCF-10A cells.J. Steroid Biochem. Mol. Biol., 2014; 143: 122–129
  Google Scholar
• 61. Yared E., McMillan T.J., Martin F.L.: Genotoxic effects of oestrogensin breast cells detected by the micronucleus assay and theComet assay. Mutagenesis, 2002; 17: 345–352
  Google Scholar
• 62. Zahid M., Gaikwad N.W., Rogan E.G., Cavalieri E.L.: Inhibitionof depurinating estrogen-DNA adduct formation by natural compounds.Chem. Res. Toxicol., 2007; 20: 1947–1953
  Google Scholar
• 63. Zielniok K., Gajewska M., Motyl T.: Molekularne aspekty działania17β-estradiolu i progesteronu w komórkowych szlakach sygnałowych.Postępy Hig. Med. Dośw., 2014; 68: 777–792
  Google Scholar

Full text